NCT02063555已完成1 期
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 2
- 主要终点
- Safety
研究概览
简要总结
This is a Phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study of DAR 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in HIV negative and HIV positive adults previously vaccinated with BCG. The goals of the trial are to determine the safety, tolerability, and immunogenicity of multiple doses of the vaccine at different dose levels, ranging from 0.1 to 1 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects: age 18-65, prior BCG vaccine (scar)
- •56 HIV negative subjects: negative ELISA for HIV (48 subjects with negative IGRA, 8 subjects with positive IGRA)
- •21 HIV positive subjects: positive ELISA for HIV, on ART (13 subjects with negative IGRA, 8 subjects with positive IGRA)
排除标准
- •pregnancy, positive serology for hepatitis B or C, active tuberculosis immunosuppression, severe medical illness
结局指标
主要结局
Safety
时间窗: 10 months
Subjects will be followed for both systemic side effects and injection site reactions
次要结局
- Immunogenicity(10 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.Pneumococcal InfectionsNCT05667740GPN Vaccines117
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT02531178AbbVie8
终止
1 期
A Study of Orally Administered IPG7236 in Healthy Adult ParticipantsAtopic DermatitisNCT05288543Nanjing Immunophage Biotech Co., Ltd63
已完成
1 期
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy SubjectsE.Coli InfectionsBloodstream InfectionNCT05277350SNIPR Biome Aps.36
已完成
1 期
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese SubjectsOtherwise Healthy Overweight or ObeseNCT03775278pH Pharma50